MoonLake Immunotherapeutics

As of October 3, 2025, MoonLake Immunotherapeutics shows a mildly bearish trend due to negative MACD and Bollinger Bands signals, despite mixed momentum indicators, and has significantly underperformed the S&P 500 with a year-to-date return of -84.43%.

As of September 19, 2025, MoonLake Immunotherapeutics shows a mildly bullish trend, supported by bullish MACD and moving averages, despite mixed signals from KST and Dow Theory.

As of September 19, 2025, MoonLake Immunotherapeutics shows a mildly bullish trend with mixed signals from MACD and Bollinger Bands, having outperformed the S&P 500 recently but underperformed year-to-date, while achieving a remarkable 642.82% return over three years.

As of September 12, 2025, MoonLake Immunotherapeutics shows a mildly bullish trend with mixed indicators, having underperformed the S&P 500 recently but significantly outperformed it over the past three years.

As of June 9, 2025, the trend for MoonLake Immunotherapeutics has shifted to mildly bearish, influenced by daily moving averages and monthly MACD signals, despite some mildly bullish indicators on the weekly timeframe.

MoonLake Immunotherapeutics is a small-cap biotechnology company focused on healthcare, currently reporting a net profit loss of $41 million and a market cap of $2.76 billion. It has no dividend yield and negative return on equity.

As of Jun 18, MoonLake Immunotherapeutics has a market capitalization of 2,760.75 million, categorizing it as a Small Cap company. As of Dec 24, Shareholder's Funds are 446.83 million and Total Assets are 477.93 million, with net sales of 0.00 million and a net profit of -147.83 million for the latest four quarters.